@RaceOncology
I take it that this has been the secret continuation of our Breast Cancer pre-clinical? Specifically expanding the synergy evaluation to include Doxo and Epi?
Does that wrap up the BC preclinical in a technical sense? Or has it now joined forces with the cardiotoxicity preclinical to create a Cardio-Protection initiative?
Ann: Breakthrough Zantrene Heart Protection Discovery, page-102
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.020(1.31%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.60 | $1.53 | $78.30K | 50.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 493 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 2773 | 1 |
View Market Depth
| Last trade - 14.41pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |